Here are links to more information on every late-breaking presentation at ACC.23.

The Kentucky physician fought back against the allegations, but his attorney's arguments were not effective enough to sway the judge. 

What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

Peter Libby, MD, a cardiovascular medicine specialist at Brigham and Women’s Hospital, explains his research into COVID-19 and how it damages the endothelium of blood vessels. 

The new study, published in PLOS ONE, included registry data from nearly 4,500 patients. While COVID-19 patients faced a heightened risk of adverse cardiovascular outcomes early on, many of those risks faded after approximately one month. 

A comparative meta-analysis found similar procedural outcomes, but higher 90-day mortality—partially attributable to a higher rate of comorbidities.

AVS, a Michigan-based medical device company, has said the funding will help accelerate research on its new Pulse P-IVL system. One clinical trial is already underway. 

A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.